Company intelligence / Profile preview

SPH Keyuan Xinhua Pharmaceutical

Beijing, Beijing, China

Ownership: Private
Employees: ~50
Development stage: Other

Overview

SPH Keyuan Xinhua Pharmaceutical is a leading Chinese pharmaceutical distributor and supply chain platform, facilitating the nationwide commercialization and distribution of imported and innovative drugs such as eravacycline (XERAVA) for serious bacterial infections and trientine tetrahydrochloride (Ke Pei Ou) for Wilson’s disease through strategic partnerships. It focuses on supply chain innovation and rapid hospital reach for novel therapies addressing unmet medical needs in China.

Therapeutic areas: Infectious DiseasesRare Diseases
Modalities: Small molecule
Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Everest Medicines (distribution of XERAVA)Orphalan (distribution of Ke Pei Ou for Wilson's disease)

Beyond the preview

Go deeper on SPH Keyuan Xinhua Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPH Keyuan Xinhua Pharmaceutical.